About Killer cell immunoglobulin-like receptor 2DL3
Killer cell immunoglobulin-like receptor 2DL3 (KIR2DL3) is a protein
from Homo sapiens identified by UniProt accession
P43628, 341 residues long.
MolForge cross-references it against 0 known binders and
70 disease associations.
Target properties
| Protein name | Killer cell immunoglobulin-like receptor 2DL3 |
|---|
| UniProt accession | P43628 |
|---|
| Gene | KIR2DL3 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 341 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (70)
Diseases linked to this target (Open Targets).
- prostate cancer · score 0.11
- prostate carcinoma · score 0.11
- Familial prostate cancer · score 0.11
- acute myeloid leukemia · score 0.11
- multiple myeloma · score 0.10
- head and neck squamous cell carcinoma · score 0.07
- chronic lymphocytic leukemia · score 0.07
- leukemia · score 0.07
- cancer · score 0.06
- Systemic lupus erythematosus · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P43628-F1 | alphafold | PREDICTED | 76.89 | — |
Amino-acid sequence (341 residues)
MSLMVVSMVC VGFFLLQGAW PHEGVHRKPS LLAHPGPLVK SEETVILQCW SDVRFQHFLL HREGKFKDTL HLIGEHHDGV SKANFSIGPM MQDLAGTYRC YGSVTHSPYQ LSAPSDPLDI VITGLYEKPS LSAQPGPTVL AGESVTLSCS SRSSYDMYHL SREGEAHERR FSAGPKVNGT FQADFPLGPA THGGTYRCFG SFRDSPYEWS NSSDPLLVSV TGNPSNSWPS PTEPSSETGN PRHLHVLIGT SVVIILFILL LFFLLHRWCC NKKNAVVMDQ EPAGNRTVNR EDSDEQDPQE VTYAQLNHCV FTQRKITRPS QRPKTPPTDI IVYTELPNAE P
Explore Killer cell immunoglobulin-like receptor 2DL3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets